跳至主要内容
临床试验/NCT00294710
NCT00294710已完成3 期

A Twenty Six-week, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension

Novartis3 个研究点 分布在 2 个国家目标入组 976 人开始时间: 2005年3月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Novartis
入组人数
976
试验地点
3
主要终点
Change from baseline in diastolic blood pressure after 52 weeks

研究概览

简要总结

This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with essential hypertension

排除标准

  • Severe hypertension
  • History or evidence of a secondary form of hypertension
  • History of myocardial infarction.
  • Other protocol-defined inclusion exclusion criteria also apply.

结局指标

主要结局

Change from baseline in diastolic blood pressure after 52 weeks

次要结局

  • Change from baseline in systolic and diastolic blood pressure after 52 weeks
  • Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 52 weeks
  • Achieve blood pressure control target of < 140/90 mmHg after 12 weeks

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验